BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25197368)

  • 1. Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation.
    Kaemmerer D; Athelogou M; Lupp A; Lenhardt I; Schulz S; Luisa P; Hommann M; Prasad V; Binnig G; Baum RP
    Int J Clin Exp Pathol; 2014; 7(8):4971-80. PubMed ID: 25197368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
    Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm.
    Kaemmerer D; Wirtz RM; Fischer EK; Hommann M; Sänger J; Prasad V; Specht E; Baum RP; Schulz S; Lupp A
    Pancreas; 2015 May; 44(4):648-54. PubMed ID: 25872131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors.
    Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Baum RP; Prasad V; Hommann M
    Int J Clin Exp Pathol; 2012; 5(3):187-94. PubMed ID: 22558472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
    Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
    Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A
    Tumori; 2011; 97(5):620-8. PubMed ID: 22158494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
    Roininen N; Takala S; Haapasaari KM; Jukkola-Vuorinen A; Mattson J; Heikkilä P; Karihtala P
    Oncology; 2019; 96(3):147-155. PubMed ID: 30282082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
    Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
    Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
    van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW
    Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms.
    Specht E; Kaemmerer D; Sänger J; Wirtz RM; Schulz S; Lupp A
    Histopathology; 2015 Sep; 67(3):368-77. PubMed ID: 25641082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
    Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
    Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
    Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors.
    Kaemmerer D; Lupp A; Peter L; Fischer E; Schulz S; Klöppel G; Hommann M
    Int J Clin Exp Pathol; 2013; 6(1):49-54. PubMed ID: 23236542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
    Kaemmerer D; Träger T; Hoffmeister M; Sipos B; Hommann M; Sänger J; Schulz S; Lupp A
    Oncotarget; 2015 Sep; 6(29):27566-79. PubMed ID: 26259237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
    J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs.
    Kasajima A; Papotti M; Ito W; Brizzi MP; La Salvia A; Rapa I; Tachibana T; Yazdani S; Sasano H; Volante M
    Hum Pathol; 2018 Feb; 72():144-152. PubMed ID: 29180250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous.
    Charoenpitakchai M; Liu E; Zhao Z; Koyama T; Huh WJ; Berlin J; Hande K; Walker R; Shi C
    Virchows Arch; 2017 May; 470(5):545-552. PubMed ID: 28213807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.